NCT05364190View on ClinicalTrials.gov

Canagliflozin in Patients With Acute Decompansted Heart Failure

PHASE3CompletedINTERVENTIONAL
Enrollment

142

Participants

Timeline

Start Date

June 4, 2022

Primary Completion Date

December 1, 2023

Study Completion Date

March 1, 2024

Conditions
Chronic Heart FailureAcute Heart FailureDiabetes Mellitus
Interventions
DRUG

Canagliflozin

Canagliflozin will be used in hospitalized heart failure patients regardless of their diabetic state.

DRUG

Empagliflozin

Empagliflozin will be used in hospitalized heart failure patients regardless of their diabetic state.

Trial Locations (1)

Unknown

National heart institute, Giza

All Listed Sponsors
collaborator

Cairo University

OTHER

collaborator

National Heart Institute, Egypt

OTHER_GOV

lead

October 6 University

OTHER